Linked Life Data

7057253

Source:http://linkedlifedata.com/resource/pubmed/id/7057253

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1982-4-20
pubmed:abstractText
A conjugated bile acid, 23-selena-25-homotaurocholic acid (SeHCAT), labeled with the gamma emitter Se-75, has been evaluated in man. Absorption and excretion were compared with that of simultaneously administered [23-14C]cholic acid. SeHCAT is absorbed quantitatively following oral administration, secreted into the bile at the same rate as cholic acid, reabsorbed from the small intestine, and resecreted. It is not absorbed when the terminal ileum has been excised or bypassed. SeHCAT is therefore the first of a new class of radiopharmaceuticals, namely, gamma-emitting tracers of the complete cycle of the enterohepatic circulation. Its use will simplify investigation of the functional state of the terminal ileum by eliminating the need to collect and process feces.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0161-5505
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
126-30
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Enterohepatic circulation in man of a gamma-emitting bile-acid conjugate, 23-selena-25-homotaurocholic acid (SeHCAT).
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't